Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

$50 million is a WAG roughly based on

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Gus McCrae Member Profile
 
Followed By 5
Posts 182
Boards Moderated 0
Alias Born 11/17/20
160x600 placeholder
CEO Presenting on the First Emerging Growth / Investors Hub Joint Conference on July 21 InvestorsHub NewsWire - 7/19/2021 7:00:00 AM
CEO Presenting on the Emerging Growth / Investors Hub Joint Conference Tomorrow.  Register Now InvestorsHub NewsWire - 7/6/2021 7:00:00 AM
Sino United (OTC Pink: SUIC) $200 Million Commitment, Signs with Suntech, the Largest Taiwan O2O Company. InvestorsHub NewsWire - 6/30/2021 7:30:00 AM
CEO Presenting on the First Emerging Growth / Investors Hub Joint Conference Tomorrow!  Register Now InvestorsHub NewsWire - 6/22/2021 7:00:00 AM
CEO's Presenting at Emerging Growth Conference Virtually This Week InvestorsHub NewsWire - 6/7/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/24/2021 4:35:22 PM
Northwest Bio gaining attention as investors await phase 3 GBM data Seeking Alpha - 5/24/2021 11:16:44 AM
CEO's Presenting at Emerging Growth Conference Virtually This Week InvestorsHub NewsWire - 5/24/2021 7:03:10 AM
IQST Signals BUY InvestorsHub NewsWire - 5/20/2021 9:43:19 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/17/2021 5:17:07 PM
CEO Presenting at Emerging Growth Conference Virtually This Week InvestorsHub NewsWire - 5/11/2021 7:00:00 AM
Nightfood, Inc. (OTCQB: NGTF) Joins Pepsico (NYSE: PEP), Unilever (NYSE: UL) and Bayer at Event InvestorsHub NewsWire - 5/5/2021 6:28:08 AM
Nightfood, Inc. (OTCQB: NGTF) in Walmart (NYSE: WMT) Coast to Coast over 1,000 Locations InvestorsHub NewsWire - 4/20/2021 7:09:50 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/31/2021 4:56:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/5/2021 8:32:22 AM
Emerging Growth Conference 2 Announced for March 3, 2021 Niche Companies in Technology, AR, eCommerce, Beverage and more .... InvestorsHub NewsWire - 3/1/2021 6:28:27 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/26/2021 4:55:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/19/2021 4:07:42 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 1/15/2021 7:21:09 AM
The FDA Calendar Review Dates Can Play a Big Role in Timing Your Trades, But Not the Way You May Think InvestorsHub NewsWire - 1/7/2021 8:00:00 AM
Biotech Companies; Recent Milestones and Potential Upside InvestorsHub NewsWire - 12/22/2020 8:05:00 AM
TNS is on the Hunt for the Next OTC Home Run Stock, Feature Report InvestorsHub NewsWire - 11/30/2020 8:20:00 AM
Immune Therapeutics, Inc. Spinoff Cytocom, Inc. Appoints BioPharm Industry Veteran as New Chief Operating Officer InvestorsHub NewsWire - 11/11/2020 9:11:00 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 11/10/2020 4:58:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/2/2020 2:16:52 PM
Gus McCrae   Tuesday, 04/27/21 11:24:22 AM
Re: Poor Man - post# 372813
Post # of 392001 
$50 million is a WAG roughly based on what I assume would be a major push to increase manufacturing capacity, pursue regulatory approvals and hire a bunch of people to run the company. It's also roughly in line with what other similarly situated biotechs go out and raise (less than most, actually).

But even if it was $25 million, I don't think they could do an offering without raising the authorized share amount, even if they technically had a little bit of room.

I'm not disagreeing with you that it looks like the company doesn't plan to be around for much longer. They certainly could be planning to sell or enter into some kind of partnership agreement. At this point, I don't have any conviction one way or another about what I think is going to happen, other than I think DCVAX-L will eventually get approved.

The thing is, DCVAX-L can get approved, be incredibly beneficial to certain patients and be a tremendous accomplishment from a science and technology perspective without the stock price going up significantly in the near term. I think a lot of people on this message board don't understand this. Of course, I hope I'm wrong and that the market immediately reflects other indications like it has for NVCR...it certainly could, maybe even should. But we have a market cap today of $1.2 billion (not including over 500 million of outstanding derivative securities). The company told us they can produce 500 vaccines a year and then said they plan to utilize the rest of the Sawston space for 3rd party contract manufacturing in the near term. So if the company's revenues are expected to be around $100 million per year for the next couple years, are we going to see $6 per share anytime soon? I don't think so, but I hope I'm wrong. Actually, I hope for a buyout because that would be in societies best interest.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences